Apogee Therapeutics, Inc.
APGEDelisted Sep 3, 2026- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001974640
Apogee Therapeutics, Inc. was delisted on Sep 3, 2026; its insiders filed their last Form 4 on Sep 3, 2026; 288 institutions reported holding it in 13F filings for Q2 2026, worth $8.93B in total; Soros Fund Management was the only superinvestor holding it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Apogee Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 3 filings
- 2 insiders, $4.14M in total
- Insiders trading
- 2
- Net value
- −$4.14M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Apogee Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Harwin Peter Evan | Director | 0Indirect | Sep 3, 2026 | 3 |
| Fairmount Healthcare Fund II L.P. | Director | 0Indirect | Sep 3, 2026 | 3 |
| Fairmount Funds Management LLC | Director | 0Indirect | Sep 3, 2026 | 4 |
| Kiselak Tomas | Director | 0Indirect | Sep 3, 2026 | 4 |
| McKenna Mark C. | Director | 0 | Sep 3, 2026 | 2 |
| Jones William A Jr | Director | 0 | Sep 3, 2026 | 2 |
| Dambkowski Carl | Chief Medical Officer | 0 | Sep 3, 2026 | 15 |
| Fox Jennifer A. | Director | 0 | Sep 3, 2026 | 2 |
| Henderson Jane | Chief Financial Officer | 0 | Sep 3, 2026 | 14 |
| Bollinger Lisa | Director | – | Sep 3, 2026 | 2 |
| Henderson Michael Thomas | Chief Executive Officer | 0 | Sep 3, 2026 | 14 |
| Shah Nimish P | Director | 0Indirect | Sep 3, 2026 | 3 |
| Gottesdiener Andrew | Director | – | Jun 20, 2025 | 0 |
| Fairmount Healthcare Fund L.P. | Director | 2,048,647Indirect | Apr 1, 2024 | 0 |
| Fairmount Healthcare Co-Invest II L.P. | Director | 51,166Indirect | Jan 31, 2024 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 13, 2026 (view filing) | Mar 11 | 2 days | Henderson Michael ThomasChief Executive Officer | SSale | −20.0K | $74.78 | −$1.50M | −1.7%1.15M after | 3 lots10b5-1 |
| Mar 27, 2026 (view filing) | Mar 25 | 2 days | Henderson JaneChief Financial Officer | SSale | −2.00K | $85.00 | −$170.0K | −1.1%179.4K after | 10b5-1 |
| Apr 3, 2026 (view filing) | Apr 1 | 2 days | Henderson JaneChief Financial Officer | SSale | −2.00K | $85.01 | −$170.0K | −1.1%177.4K after | 2 lots10b5-1 |
| Apr 3, 2026 (view filing) | Apr 1 | 2 days | Dambkowski CarlChief Medical Officer | SSale | −5.50K | $84.84 | −$466.6K | −2.6%208.4K after | 3 lots10b5-1 |
| Apr 10, 2026 (view filing) | Apr 8 | 2 days | Henderson Michael ThomasChief Executive Officer | SSale | −20.0K | $82.58 | −$1.65M | −1.7%1.13M after | 3 lots10b5-1 |
| Apr 17, 2026 (view filing) | Apr 16 | 1 day | Henderson JaneChief Financial Officer | SSale | −2.00K | $90.00 | −$180.0K | −1.1%175.4K after | 10b5-1 |
| May 4, 2026 (view filing) | May 1 | 3 days | Henderson JaneChief Financial Officer | SSale | −2.00K | $82.04 | −$164.1K | −1.1%173.4K after | 3 lots10b5-1 |
| May 8, 2026 (view filing) | May 6 | 2 days | Dambkowski CarlChief Medical Officer | SSale | −5.50K | $84.14 | −$462.8K | −2.6%207.0K after | 2 lots10b5-1 |
| May 15, 2026 (view filing) | May 13 | 2 days | Henderson Michael ThomasChief Executive Officer | SSale | −20.0K | $82.09 | −$1.64M | −1.8%1.12M after | 2 lots10b5-1 |
| Jun 5, 2026 (view filing) | Jun 3 | 2 days | Dambkowski CarlChief Medical Officer | SSale | −5.50K | $78.71 | −$432.9K | −2.6%205.6K after | 10b5-1 |
| Jun 12, 2026 (view filing) | Jun 10 | 2 days | Henderson Michael ThomasChief Executive Officer | SSale | −20.0K | $83.38 | −$1.67M | −1.8%1.10M after | 6 lots10b5-1 |
| Jun 24, 2026 (view filing) | Jun 22 | 2 days | Henderson Michael ThomasChief Executive Officer | SSale | −80.0K | $132.54 | −$10.6M | −7.3%1.02M after | 10b5-1 |
| Jun 24, 2026 (view filing) | Jun 22 | 2 days | Dambkowski CarlChief Medical Officer | SSale | −26.4K | $132.60 | −$3.50M | −12.8%179.2K after | 10b5-1 |
| Jul 2, 2026 (view filing)8:13 PM ET | Jul 1 | 1 day | Dambkowski CarlChief Medical Officer | SSale | −5.50K | $132.74 | −$730.1K | −3.0%177.9K after | 10b5-1 |
| Jul 10, 2026 (view filing)8:00 PM ET | Jul 8 | 2 days | Henderson Michael ThomasChief Executive Officer | SSale | −20.0K | $133.63 | −$2.67M | −2.0%996.0K after | 10b5-1 |
| Aug 7, 2026 (view filing)8:00 PM ET | Aug 5 | 2 days | Dambkowski CarlChief Medical Officer | SSale | −5.50K | $134.17 | −$737.9K | −3.2%168.5K after | 10b5-1 |